Compass Therapeutics, Inc. Common Stock (CMPX) Stock Price
CMPXStock
$2.53−14.29%52W
Market Cap$455.62M
P/E—
PEG Ratio—
Div yield—
Beta0.88
CMPX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-74.58%
Price vs S&P 500 (4W)11.78%
VGM Score54.16
CMPX Earnings Surprise History
Q2 25-0.14est. -0.12
Q3 25-0.08est. -0.13
Q4 25-0.09est. -0.09
Q1 26-0.10est. -0.10
Q2 26-0.13est. -0.11
CMPX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.29
4.30
4.30
4.33
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CMPXCompass Therapeutics, Inc. Common Stock | — | — | C | $2.53 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Compass Therapeutics, Inc. Common Stock
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing antibody-based immunotherapies to treat cancer. The company uses proprietary antibody discovery platforms and bispecific engineering capabilities to design targeted therapeutic combinations with favorable manufacturing profiles. Its pipeline includes multiple candidates such as CTX-009, CTX-471, CTX-8371, and a VEGF-A bispecific, leveraging its StitchMabs and common light chain technologies to advance treatment options.